Viking Therapeutics
VKTX
6 hedge funds and large institutions have $384K invested in Viking Therapeutics in 2015 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$196K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$151K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$94.3K |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$2.71K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.53K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Goldman Sachs
New York
| $169K | +$196K | +23,694 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $130K | +$151K | +18,275 | New |
|
|
VKH
3
Virtu KCG Holdings
New York
| $81K | +$94.3K | +11,403 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $2K | +$2.53K | +306 | New |
|
|
BIM
5
BlackRock Investment Management
Wilmington,
Delaware
| $2K | +$2.71K | +327 | New |
|
6
Morgan Stanley
New York
| – | +$132 | +16 | New |
|
VKTX Hedge Fund Activity: Q2 2015 in Review
6 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2015, worth a combined $384K.
Buyers outnumbered sellers: 6 funds opened new VKTX positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $196K.
- 6 institutional investors held Viking Therapeutics (VKTX) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $384K of Viking Therapeutics stock for Q2 2015.
- 6 funds opened new Viking Therapeutics positions in Q2 2015 and 0 closed out, a net change of +6 holders.
- The largest Viking Therapeutics buyer in Q2 2015 was Goldman Sachs, an estimated $196K added.
Based on aggregated 13F filings for Q2 2015.